
Publication|Articles|October 16, 2025
Pharmacy Practice in Focus: Oncology
- October 2025
- Volume 7
- Issue 7
Current and Emerging BCMAxCD3 Bispecifics
Author(s)Rebekah R. Dyer, PharmD, BCPS
Advertisement
Advertisement
In the past 10 years, bispecific antibodies have revolutionized the treatment algorithm for relapsed or refractory multiple myeloma. To date, there are 3 BCMA-directed bispecific antibodies that treat RRMM: teclistamab, elranatamab, and linvoseltamab. Therapy sequence and distinctions among agents are a current clinical conundrum. Ongoing research focuses on drug differences, order of agents, managing resistance, and mitigating adverse effects to improve outcomes in multiple myeloma.
Related to this article

How should a factor XIa inhibitor be incorporated into secondary stroke prevention?

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.

Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Advertisement
Advertisement


